Request Demo

Last update 16 May 2025

Lorazepam

Last update 16 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryLorazepam, a minute molecular compound, acts as an agonist that targets the GABAA receptor. It boasts a varied scope of medical uses, such as assuaging anxiety disorders, depressive disorder, epilepsy, sleep initiation and maintenance disorders, and even catatonia in Down Syndrome patients. Initially greenlighted by Bausch Health in 1970, this drug ushers in a binding process, whereby the GABAA receptor in the central nervous system is targeted, and subsequently leads to heightened GABAergic inhibitory neurotransmission, which deftly quashes neuronal activity and thus facilitates sedative, anxiolytic, and anticonvulsant effects. Despite the benefits of this medication, it is prudent to bear in mind the potential for adverse effects, which may include drowsiness, dizziness, and impaired coordination. With prolonged usage, there is a possibility of developing dependence on the drug, hence why it is indispensable to utilize Lorazepam only under the watchful eye of a competent healthcare provider.

Drug Type

Small molecule drug

Synonyms

Lora-Pita Intravenous, Lorazepam (JP17/USP/INN), o-Chlorooxazepam

+ [17]

Target

GABAA receptor

Action

agonists

Mechanism

GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists)

Therapeutic Areas

Nervous System DiseasesOther DiseasesCongenital Disorders

Active Indication

Sleep Initiation and Maintenance DisordersSedationStatus Epilepticus+ [4]

Inactive Indication

Generalized anxiety disorder

Originator Organization

Bausch Health Cos., Inc.

Active Organization

Hikma Pharmaceuticals USA, Inc.Bausch Health US LLC

Hunan Dongting Pharmaceutical Co., Ltd.

+ [5]

Inactive Organization

Pfizer Inc.

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (30 Sep 1977),

Anxiety DisordersDepressive Disorder

Regulation-

Structure/Sequence

Molecular FormulaC15H10Cl2N2O2

InChIKeyDIWRORZWFLOCLC-UHFFFAOYSA-N

CAS Registry846-49-1

128

Clinical Trials associated with Lorazepam

NCT06852469

/ Not yet recruitingPhase 4IIT

Individualized Computational Assessment of the Effects of GABA Receptor Modulation in Posttraumatic Stress Disorder

A substantial majority of Veterans with posttraumatic stress disorder (PTSD) continue to suffer even with the best current medications. Progress in developing more effective medications is hampered by the substantial variability within Veterans with PTSD, meaning the most effective medication likely varies from individual to individual. New scientific tools to help identify distinct subgroups of Veterans with PTSD who are likely to respond to specific medications could help improve treatment in this population. Research has indicated that a specific subgroup of Veterans with PTSD with a high level of anxious arousal may benefit from medications which boost signaling of the neurotransmitter gamma-aminobutyric acid (GABA). This project aims to validate a clinical test to identify these individuals using new computational and neuroimaging methods combined with the medication lorazepam, a positive GABA modulator. The ultimate goal is to use these methods in future clinical trials of new medications to target the best treatments to individual Veterans with PTSD.

Start Date01 Jul 2025

Sponsor / Collaborator

VA Office of Research and Development

NCT06496854

/ Not yet recruitingPhase 2IIT

Prescribing Lorazepam for IUD Insertion: Pilot Feasibility Study

The objective of this pilot study is to discuss the feasibility of prescribing lorazepam prior to IUD insertion and of measuring effect of lorazepam on anxiety and pain with Intrauterine Device (IUD) insertion. The target population for this study will be 25 adult participants scheduled for an IUD insertion at a UW Family Medicine residency clinic. Participants will be followed for 1 appointment visit.

Start Date01 Jun 2025

Sponsor / Collaborator

University of Wisconsin Madison

NCT06799494

/ Not yet recruitingPhase 4IIT

Comparing the Antibody and B Cell Responses Induced by 1- or 2-dose 9-valent HPV (9vHPV) Vaccination in Healthy Adults

This study aims to answer the question: does 1-dose HPV vaccination generate the same immune responses compared to 2- or 3-dose HPV vaccination? This will be done by studying the immune response in blood, lymph nodes, and bone marrow.
Human papillomaviruses (HPV) cause cancers (cervical, anal, oropharyngeal, vulvar, vaginal, and penile), and the current HPV vaccine is highly effective at preventing disease by HPV types that cause 90% of cancer cases. While this vaccine generates high levels of antibodies that last for > 10 years, understanding of how this occurs is limited, and studying this immune response will help design new and better vaccines.
The study population consists of healthy adult (age 18-45) participants who have not previously received an HPV vaccine, do not have antibodies against certain types of HPV, do not have a history of HPV infection or disease (such as genital warts, abnormal pap test, or HPV DNA test), and do not have contraindications to study procedures. Populations of increased concern are not being enrolled.

Start Date01 May 2025

Sponsor / Collaborator

Emory University

[+1]

100 Clinical Results associated with Lorazepam

100 Translational Medicine associated with Lorazepam

100 Patents (Medical) associated with Lorazepam

8,097

Literatures (Medical) associated with Lorazepam

01 Jun 2025·FOOD CHEMISTRY

High-throughput screening of new psychoactive substances and related compounds in food by UHPLC-Q/Orbitrap

Article

Author: Huang, Xia ; Wan, Yuping ; Shi, Peiyu ; Wu, Wenlin ; Xiao, Quanwei ; Liu, Shiyao ; Guo, Tianrong ; Chen, Xiaoqi ; Zhang, Min ; Xia, Bing ; Zhou, Yan

Currently, there is concern about food products to which new psychoactive substances (NPS) have been added illegally. However, rapid, high-sensitivity, and high-throughput screening methods for such harmful substances have not been reported yet. In this study, a high-throughput non-targeted screening strategy was developed based on UHPLC-Q/Orbitrap. First, optimized pretreatment methods for typical high-risk matrices were established. Second, an accurate, efficient, and scalable high resolution mass spectrometry database containing 206 NPS and related compounds was constructed. The fragmentation pathways of three different types of fentanyl-related compounds were then systematically investigated to enhance compound identification. Additionally, a non-targeted screening strategy was developed using warning ions derived from 24 fentanyl-related compounds, streamlining the identification of NPS. This strategy was applied to 100 food samples with possible illegal additives and demonstrated its effectiveness. In summary, this study provides robust technical support for regulatory authorities in combating the illegal addition of food products.

04 May 2025·Expert Opinion On Drug Safety

Compartment syndrome associations with drugs: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)

Article

Author: Yang, Xueting ; Shu, Yunfeng ; Tang, Juan ; Kong, Wenqiang ; Wan, Jie

BACKGROUND:

Compartment syndrome is an uncommon but life-threatening condition. No study has comprehensively compared compartment syndrome (CS) association with available drugs. The objective of this study was to estimate the association between CS and drugs using the FDA Adverse Event Report System (FAERS).

RESEARCH DESIGN AND METHODS:

FAERS reports from the first quarter of 2004 to the third quarter of 2023 were analyzed. The Medical Dictionary for Regulatory Activities (MedDRA) was used to identify CS cases. Reporting odds ratio (ROR), corresponding to 95% confidence intervals (95% CI) were calculated to detect a positive signal.

RESULTS:

A total of 2197 reports were considered in the study after the inclusion criteria were applied. Totally 100 drugs were found to be associated with CS. The median time for drug-associated CS was 45 days.

CONCLUSIONS:

By analyzing the FAERS database, the study revealed that certain drugs are significantly associated with compartment syndrome. Further studies are needed to verify whether these drugs are associated with such a risk.

04 May 2025·Expert Opinion On Drug Safety

Anti-seizure medications-associated bladder and urethral symptoms: a pharmacovigilance analysis based on the FAERS database

Article

Author: Wu, Zhanshen ; Li, Yanyan ; Shi, Lei ; Zhao, Yang

BACKGROUND:

In clinical practice, observations have been made regarding bladder and urethral symptoms (BUS), notably urinary frequency and urgency, among patients prescribed the anti-seizure medication (ASM) lacosamide. However, the precise association between ASMs and BUS events in real-world settings remains elusive.

RESEARCH DESIGN AND METHODS:

Data from the FDA Adverse Event Reporting System (FAERS) database were employed and the analysis focused on ASMs-associated BUS events utilizing disproportionality analysis methods, including the reporting odds ratio (ROR) and the proportional reporting ratio (PRR). Furthermore, co-administration, time to onset of ASMs-associated BUS events, and severity assessments were conducted.

RESULTS:

Several ASMs demonstrated statistically meaningful associations with BUS signals, notably ezogabine, valproic acid/valproate sodium, and clorazepate (p < 0.05). And ASMs-associated BUS events predominantly occurred within the first week and persisted for more than 180 days afterward. Diazepam, gabapentin, and brivaracetam exhibited distinct risk profiles for severe BUS events compared to valproic acid/sodium valproate (p < 0.05). And the nomogram constructed in this study exhibited robust predictive performance.

CONCLUSION:

This study yields valuable insights into the association between ASMs and BUS events, but several limitations warrant consideration. Nonetheless, these findings emphasize the significance of vigilance and proactive management of ASMs-associated BUS events.

News (Medical) associated with Lorazepam

27 Feb 2025

·www.drugs.com

Opioids During Surgery Might Cause Worse Pain For Patients

THURSDAY, Feb. 27, 2025 -- Powerful synthetic opioids are meant to serve as painkillers, but new research suggests their use during surgery might actually prompt worse pain during patients’ recovery. The use of two types of synthetic opioid during surgery is linked to patients having a poor “pain experience” -- a composite of the emotional, cognitive and mental aspects of pain, researchers said. In fact, the use of remifentanil and sufentanil during surgery increased 27-fold a patient’s risk of suffering as they recover, researchers reported Feb. 25 in the journal Regional Anesthesia & Pain Medicine . While opioid drugs can help quell pain following surgery, “their intraoperative administration -- especially of potent agents like remifentanil and sufentanil -- may paradoxically contribute to heightened postoperative pain,” concluded the research team led by Dr. Axel Maurice Szamburski , an associate professor of anesthesiology with the University Hospital Center Nice Pasteur Hospital in Nice, France. Most patients experience moderate to severe pain following surgery, researchers said in background notes. This isn’t just unpleasant for them, but can hinder their recovery and increase their risk of complications. “Identifying key determinants of a poor pain experience could help uncover areas of care that, when addressed, may improve patient satisfaction and reduce the risks of both acute and chronic postsurgical pain,” researchers wrote. For this study, researchers analyzed data gathered for 971 patients as part of a clinical trial aimed at evaluating the effectiveness of sedatives given prior to surgery. The patients, all younger than 70, had been randomly assigned the day before surgery to receive the sedative lorazepam , a placebo, or nothing at all. Their surgeries took place at five French teaching hospitals. About 37% of the surgeries were orthopedic or spinal; 29% involved the ear, nose or throat; and 15% digestive, the study says. Of those patients, 271 (28%) reported a poor pain experience on their first day following surgery, based on a questionnaire aimed at capturing all the mental and physical aspects of pain. The use of powerful opioids while patients were under general anesthesia increased their risk of pain during recovery by about 27 times, researchers found. This is consistent with a known phenomenon called “opioid-induced hyperalgesia, where exposure to a high dose of opioids can lead to an increased sensitivity to pain stimuli,” researchers wrote. Patients also were five times more likely to have serious pain if they have a severe chronic illness, and eight times more likely if they were given drugs following surgery to treat anxiety, results show. People were 51% less likely to have pain if they were given no preoperative sedatives, and 71% less likely if they had undergone orthopedic surgery. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

12 Sep 2024

·www.biospace.com

The API Innovation Center Receives $14 Million in Strategic Funding to Bolster U.S. Pharmaceutical Independence

Biden-Harris Administration funds first Defense Production Act Title III award to onshore manufacturing of ingredients for essential medicines ST. LOUIS--(BUSINESS WIRE)--The API Innovation Center (APIIC) today announced that it has been awarded funding by the Administration for Strategic Preparedness and Response’s (ASPR) Center for Industrial Base Management and Supply Chain (IBMSC) to lead the development and domestic production of three critical active pharmaceutical ingredients (APIs) used in the treatment of asthma, diabetes, and anxiety disorders. APIIC will leverage advanced manufacturing technologies and cutting-edge research to further national strength in pharmaceutical innovation and supply chain resilience. The BioMaP-Consortium is a multi-purpose acquisition vehicle comprised of industry partners across the drug and vaccine manufacturing supply chain supported by ASPR’s Biomedical Advanced Research and Development Authority (BARDA). IBMSC will provide $14 million in funding and APIIC will invest an additional $2.4 million into the development of these critical APIs. This funding marks a significant step forward in securing the U.S. pharmaceutical supply chain and addressing national health security risks. At least 83% of the nation’s top 100 generic medicines have no U.S.-based source for the small-molecule APIs found in today’s medication. This dependency on foreign manufacturers has left the U.S. pharmaceutical supply chain vulnerable to shortages and geopolitical conflicts while domestic facilities operate below capacity. The decrease in U.S.-based production for APIs and key starting materials (KSMs) used to make them is widely recognized as a major driver behind this significant national health security risk. While much work remains to improve the return on investment for developing medicines domestically, funding through the BioMaP-Consortium represents a key investment in the ongoing efforts to reshore critical medicines and address ever-increasing drug shortages. Initiative to Address Availability of Essential Medications This initiative will see APIIC lead the development and production of three critical APIs, each chosen for their vital role in U.S. health care, shortage history, as well as inclusion on essential medicines lists: Albuterol: Used to treat asthma and other respiratory conditions. Desmopressin Acetate: Used to treat diabetes insipidus & blood coagulation conditions. Lorazepam: Used to treat anxiety. “This funding represents both a financial commitment and a significant step towards securing America’s pharmaceutical resiliency and patient access to critical medicines. By focusing on developing these high-impact molecules, we are creating a private-public blueprint for driving self-reliance that is essential for national health security and can be replicated across the country,” said Tony Sardella, chair and founder of APIIC. Partnership and Impact This project harnesses the strengths of APIIC’s extensive partner network, including collaborations with leading universities, pharmaceutical manufacturers, and suppliers of KSMs. APIIC will unite the resources and advanced manufacturing technologies of Mallinckrodt Specialty Generics, Apertus Pharmaceuticals, MilliporeSigma, and the University of Missouri–St. Louis (UMSL) to enhance the quality, efficiency, and global competitiveness of U.S.-based pharmaceutical manufacturing. These strategic collaborations form a dynamic product team, capitalizing on each member’s specific expertise, with APIIC providing funding and support to harness their strengths and advanced manufacturing capabilities. “Mallinckrodt Specialty Generics is proud to partner with the API Innovation Center on this critical initiative to bolster the U.S. pharmaceutical supply chain. Our proven expertise in the development, manufacture, and commercialization of active pharmaceutical ingredients in the U.S. positions us extremely well to contribute to this effort. By collaborating with APIIC and its partners, we are both addressing the nation’s drug shortage challenges and strengthening the nation’s ability to manufacture essential medicines domestically,” said Stephen Welch, executive vice president & head of Mallinckrodt Specialty Generics. APIIC will collaborate closely with Apertus Pharmaceuticals on research and development work, leveraging advanced manufacturing technology to produce these critical molecules. “Collaborating with the API Innovation Center has enabled us to scale our cutting-edge research and play a key role in this national initiative to strengthen our pharmaceutical supply chain,” said David Gindelberger, chief executive officer of Apertus Pharmaceuticals. MilliporeSigma, a small and large molecule contract development and manufacturing organization (CDMO) with facilities in St. Louis, will also play a pivotal role. “We are excited to bring our 25 years of CDMO expertise in organic synthesis and bioconjugation of ADCs, producing Active Pharmaceutical Ingredients (API), excipients and critical raw materials, to this partnership. This initiative will not only mitigate risks associated with supply disruptions but can also enhance the U.S. bioeconomy,” said Mark Cooley, site director of one of the St. Louis MilliporeSigma facilities involved in the consortium. “Partnering with the API Innovation Center on this important initiative allows us to leverage our strengths in research, workforce development, and community engagement to support a more secure and self-reliant pharmaceutical supply chain. UMSL is proud to play a key role in advancing these critical efforts, which will have lasting impacts on both our region’s economy and the nation’s health security,” said Dr. Chris Spilling, vice chancellor for research and economic and community development at the University of Missouri-St. Louis. A Roadmap for a Resilient Supply Chain in Missouri APIIC, together with the State of Missouri and the Missouri Technology Corporation, has been developing a state-supported model in the St. Louis region and a strategic framework for creating a resilient national pharmaceutical manufacturing ecosystem. This model is designed to be a replicable blueprint that compliments Missouri’s strengths in infrastructure and workforce development to restore U.S. leadership in pharmaceutical production. To date, the State of Missouri has committed approximately $18 million to API reshoring efforts, demonstrating to other states how to support the “Missouri Model” and take the lead in addressing national supply chain challenges. “Missouri is leading in restoring America’s pharmaceutical manufacturing strength. By focusing on developing active pharmaceutical ingredients right here in Missouri, we are tackling a pressing national health security issue—our over-reliance on foreign suppliers,” said Gov. Mike Parson. “Recognizing our strengths, particularly in pharmaceutical manufacturing, we collaborated with the General Assembly to invest in bringing critical medicine production back to the U.S. The state’s investment, now bolstered by federal support, is a clear indicator that what we are doing in Missouri is working. We are not just talking about solutions. We’re delivering results that are necessary steps toward safeguarding the health and security of our nation.” As it looks to the future, APIIC is committed to driving the U.S. towards pharmaceutical self-reliance, ensuring every hospital, pharmacy, and patient has access to domestically produced critical medication to support national health security. This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Office of Industrial Base Management and Supply Chain (IBMSC), under OT number #75A50123D00003. About the API Innovation Center: The API Innovation Center (APIIC) is a 501(c)(3) nonprofit public benefit organization headquartered in St. Louis, Missouri, dedicated to driving health security and economic growth for the nation and its citizens through U.S.-based production of critical medicines. By investing in and collaborating along the supply chain, APIIC’s model contracts with leading U.S.-based specialists within their pharmaceutical ecosystem to develop and manufacture high-quality domestically produced Active Pharmaceutical Ingredients. APIIC is also committed to expanding access to critical medications through strategic partnerships to commercialize market-competitive supplies of finished drug products and build resiliency in the supply chain. Their mission is to ensure every hospital, pharmacy, and patient has access to domestically produced critical medication to fortify national health security. APIIC is supported by the state of Missouri through the Advanced Manufacturing Resiliency Grant awarded by the Missouri Technology Corporation. To learn more, visit: apicenter.org . About Apertus Pharmaceuticals: Apertus Pharmaceuticals is a contract development and manufacturing organization (CDMO) that develops and manufactures device, OTC and prescription pharmaceutical products. Services include product de-formulation, formulation development, process development, and manufacturing (clinical batch to intermediate scale), including product serialization. Apertus performs an extensive range of analytical method development and validation as well as provides stability programs for all of the medications it produces. Apertus currently manufactures solid oral dose, suppository, liquid and cream products. Apertus is cGMP compliant and maintains Drug Enforcement Administration research and analytical registrations for Schedules II-V. To learn more about Apertus Pharmaceuticals, visit: apertuspharma.com . About Mallinckrodt Specialty Generics: Mallinckrodt’s Specialty Generics business segment is a 150+ year-old business that manufactures approximately 50 FDA-approved active pharmaceutical ingredients and approximately 100 FDA-approved finished dose pharmaceutical products across our network of U.S.-based manufacturing sites. To learn more about Mallinckrodt Specialty Generics, visit . About the Life Science business of Merck KGaA, Darmstadt, Germany The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 27,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics. Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn . About the University of Missouri–St. Louis: A Tier 1 national university and Carnegie R2 classification—Doctoral University with High Research Activity— public research university, UMSL, and its four-campus University of Missouri System, provides strong research programs in chemical organic synthesis and advanced pharmaceutical manufacturing methods, such as continuous flow technologies, along with strong industry partnerships. To learn more about the University of Missouri–St. Louis, visit: umsl.edu . Contacts Kaylee Schreiner kaylee.schreiner@fleishman.com

Acquisition

16 Jul 2024

·www.prnewswire.com

Benzodiazepine Drugs Market to Reach US$ 3.2 Billion by 2034, Growing at 3.5% CAGR | Impact of Psychological Conditions and Aging Population - Reports TMR

Benzodiazepine drugs are vastly used as psychoactive drugs, which can be used to control seizures, alcohol withdrawal symptoms, and other issues related to the psychological conditions of a human being. With the activity of drugs closely related to brain stimulation, the drug can act as a relaxant for muscles in the body. WILMINGTON, Del., July 16, 2024 /PRNewswire/ -- Owing to different governing factors, the development of the benzodiazepine drug market is expected to traverse a sluggish path of advancement during the forecasted period. With a CAGR of 3.5%, the industry will proceed to reach USD 3.2 billion by 2034. The last recorded size of the ecosystem was USD 2.2 billion in 2023. With the changing lifestyles and mounting pressures to cope with an accelerated pace of living, many people have been facing psychological issues. The growing prevalence of trauma, anxiety, mental fatigue, and many other psychological conditions is observed to have increased recently. To treat such medical conditions, an appropriate relaxant must be applied to get the desired results. This growing prevalence is a clear sign of an important driver that promises to elevate the size of the competitive space during the forecasted period. The rising geriatric population is contributing to the growing cases of insomnia. Along with the abovementioned factors, the growing senior population is trying to find solutions for issues like sleep deprivation. To cater to such issues, the use of benzodiazepine drugs is observed to have increased. Propel Your Business Success: Secure Your Sample of Our Latest Report Now! Due to the sedative properties of drugs, the use of such chemicals is observed to have gained traction in the case of muscle relaxants. To cater to such muscle spasms and other related issues, such drugs can be effective. This factor drives the sales of such drugs. With the spurring of innovation and growth in the technological infrastructure, product augmentation has become possible. Key players in the ecosystem invest more in innovation to alter formulations of drugs. This elevates drug delivery and response time, delivering better results. Rising investments in the pharmaceutical and healthcare industries have generated better prospects for leading organizations. As more market openings have been created in the industry, the scope of expanding the market increases for key players, benefitting the size of the industry. The growing research and development activities are expected to augment the drug efficacy and efficiency, which will likely benefit the industry. Due to this, such efforts have been fueling the industry's progress, creating opportunities for new entrants. Benzodiazepine Drugs Market Report Scope: Key Findings from the Market Report The competitive landscape of benzodiazepine drugs can be segmented into different categories depending on various parameters. Based on the drug type, Alprazolam is used to control anxiety issues. The drug controls an abnormal excitement in the brain. Based on the application segment, anxiety is the largest shareholder in the industry. Due to the changing lifestyle, such cases are increasing at an alarming rate, gaining more demand for the segment. Based on the time of use, various prolonged cases of such drugs are seen to have gained momentum. Curing deep psychological impacts is surging the demand for the segment. Based on the end-user, hospital pharmacies govern the largest market share due to better availability of drugs. Regional Profile The growing awareness of psychological health in Asia-Pacific is creating better prospects for the global benzodiazepine drug market. With the growing drug research activities in Europe, the demand for such drugs will likely increase due to a larger canvas. The progress of the healthcare and pharmaceutical industry in North America is a key factor in helping the region lead the global landscape. Competitive Landscape Among different firms expanding in the industry, Pfizer Inc. is a key player that produces different products to expand. Such products include aminophylline, etomidate, argatroban injection, and many more. UCB S.A. is another important player producing solutions for Briviact (brivaracetam) Epilepsy, Ankylosing spondylitis, and Myasthenia Gravis. Hikma Pharmaceuticals PLC operates in different verticals, including injectables, oral drugs, and other segments. Key Developments in the Benzodiazepine Drug Market In December 2023, Pfizer Inc. acquired Seagen. This move bolstered the position of the organization in the industry. In March 2024, UCB S.A. invested in IMIDomics, Inc. to innovate solutions for immune-mediated inflammatory diseases. This product launch helped the business augment products, bolstering the position in the market. Key Players Pfizer Inc. UCB S.A. Hikma Pharmaceuticals PLC Teva Pharmaceutical Industries Ltd. H.Lundbeck A/S Apotex Inc. Aurobindo Pharma Purdue Pharma Other Prominent Players Market Segmentation Drug Type Alprazolam Clonazepam Diazepam Lorazepam Others (Midazolam, etc.) Application Anxiety Insomnia Alcohol Withdrawal Seizures Others (Bipolar Disorder, etc.) Time of Action Ultra-short Acting Short Acting Long Acting End User Hospital Pharmacies Retail Pharmacies Online Pharmacies Region North America Europe Asia Pacific Latin America Middle East & Africa Drive Your Business Growth Strategy: Purchase the Report for Key Insights! Have a Look at Related Research Reports of Pharmaceutical Cardiovascular Drugs Market - The global cardiovascular drugs market, valued at USD 142.8 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of 3.8% from 2023 to 2031. This growth trajectory is expected to elevate the market size to USD 195.6 billion by the end of 2031, driven by increasing prevalence of cardiovascular diseases, advancements in drug development, and rising healthcare expenditures globally. Insomnia Market - The global insomnia industry was worth US$ 3.8 billion in 2022. From 2023 to 2031, it is expected to increase at a CAGR of 6.0%, reaching US$ 6.4 billion. Various therapies have been explored for managing insomnia, offering non-pharmacological alternatives for those seeking sleep improvement. Bioengineered Protein Drugs Market - Rise in incidence of chronic diseases such as infectious diseases, autoimmune disorders, and cancer is a dominating factor contributing to the bioengineered protein drugs market growth. About Transparency Market Research Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. Contact: Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: Email: [email protected] Follow Us: LinkedIn | Twitter | Blog | YouTube Logo: SOURCE Transparency Market Research

Acquisition

100 Deals associated with Lorazepam

External Link

KEGG	Wiki	ATC	Drug Bank
D00365	Lorazepam	N05BA06	DB00186

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Sleep Initiation and Maintenance Disorders	China	Hunan Dongting Pharmaceutical Co., Ltd.	10 Oct 2003
Sedation	United States	Hikma Pharmaceuticals USA, Inc.	25 Jul 1980
Status Epilepticus	United States	Hikma Pharmaceuticals USA, Inc.	25 Jul 1980
Catatonia	Japan	Pfizer Japan, Inc.	04 Nov 1977
Anxiety Disorders	United States	Bausch Health US LLC	30 Sep 1977
Depressive Disorder	United States	Bausch Health US LLC	30 Sep 1977

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Down Syndrome	Phase 2	United States	The University of Colorado	22 Dec 2022
Generalized anxiety disorder	Clinical	United States	Pfizer Inc.	01 Oct 2003

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ATS2024	Not Applicable	-	-	Intravenous Benzodiazepines	cwydypmivp(avptphivlr) = tfctyukirp taagjwyuqi (vtomwzvwfx )	-	19 May 2024
IEC2023	Not Applicable	Epilepsies, Myoclonic	-	Lorazepam	dbxwfaqlag(qbcqnddxws) = kggxsdnqxj sgqwuoyiel (obyievgrlu )	-	04 Sep 2023
				Valproic acid	dbxwfaqlag(qbcqnddxws) = ewrmvcliow sgqwuoyiel (obyievgrlu )
NCT00721526 (CTgov)	Phase 4	Alcoholism \| Anxiety Disorders	41	disulfiram+lorazepam	nhokgjuegr = suzvqihvmx solpwvbxvf (bdzbercatj, nljbsgrhuo - vgwrwhijvc) View more	-	30 Aug 2023
NCT03090620 (TAAT, CTgov)	Phase 4	Toxicity	19	Physostigmine (Physostigmine)	tdwcpqanvq(miwoisoqzq) = ixzxuazgjc phyhtxsuks (wvpqlmtlnz, edkrtkvosp - mdvvsevrod) View more	-	23 Aug 2021
				Lorazepam (Lorazepam)	tdwcpqanvq(miwoisoqzq) = xympyjiwwk phyhtxsuks (wvpqlmtlnz, bnopukadab - ifgxxfzpfi) View more
NCT01949662 (CTgov)	Phase 2	Delirium \| Advanced cancer	93	Lorazepam+Haloperidol (Intervention Group (Lorazepam & Haloperidol))	fgwpbyxzih(banpwznvby) = uszbhxucti eweuitpjwc (ulugvmzezk, qkjhvpuimu - frhjnniogk) View more	-	30 Oct 2020
				Placebo+Haloperidol (Control Group (Placebo & Haloperidol))	fgwpbyxzih(banpwznvby) = gyhdblijzx eweuitpjwc (ulugvmzezk, ghkpiozvdx - thmkchrxyc) View more
NCT03202550 (OSDI, CTgov)	Phase 4	Pain	27	Placebo Comparator (Placebo Arm)	gywixukgop(yvjzoixlbr) = awqqlxnoar wylraofqvh (zlgegnfazg, wpbtmuoicv - morqjlolfe) View more	-	06 Mar 2020
				Lorazepam+Oxycodone (Active Drug Arm: Lorazepam and Oxycodone)	gywixukgop(yvjzoixlbr) = trzxhswztm wylraofqvh (zlgegnfazg, jesiujenfi - dqqqyzszyd) View more
NCT03756038 (CTgov)	Phase 2	Respiratory Distress Syndrome \| Acute Pain	1	Lorazepam (Drug: Oral Lorazepam (1mg))	swrepvsnan = glqrrdkana oyljhievhw (efveejwvrx, lghydjwbdo - nbnrsfnqrq) View more	-	26 Feb 2020
				Placebos (Drug: Oral Placebo)	vrxyrarmig(bowfvxcfxv) = hymikiqxkc ywahayzxsq (blwoipqiye, znqgorosnb - kokmbnvlnx) View more
NCT03180632 (Pubmed \| Paediatr Drugs)	Phase 2	-	101	Oral Lorazepam	ncdcarilam(fsvrkyvqht) = odnahimtwa ewdyuyfnfz (lcokzabcri ) View more	Positive	01 Oct 2019
				Placebo	ncdcarilam(fsvrkyvqht) = wgtyoxlexn ewdyuyfnfz (lcokzabcri ) View more
NCT00457366 (CTgov)	Phase 4	Agitation	72	Quetiapine	lxglvqmrfr(chgnfnsixk) = uvnxawsclj fakneksscb (uqfemlgabp, 0.69) View more	-	05 Jul 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis